4,901 trials
Healthy
Primary: Percentage of Subjects With Investigator Defined Drug-Related Adverse Events — 50.0; 50.0; 66.7; 50.0 Percentage of subjects
Healthy
Primary: Area Under the Concentration-time Curve of BI 474121 in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞) — NA; NA hours*nanomole/Liter
Healthy
Primary: Maximum Exposure-related Change From Baseline (Calculated as Ratio) of Cyclic Guanosine Monophosphate (cGMP) in Cerebrospinal Fluid (CSF) — NA; NA; NA; NA maximum change…
Healthy
Primary: Percentage of Participants With Drug-related Adverse Events — 40.0; 75.0; 50.0; 75.0 Percentage of participants
Healthy
Primary: Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Tepotinib — 25101; 16738 hours* nanograms per milliliter(h*ng/mL)
Healthy
Primary: Number of Young and Elderly Subjects With On-treatment Adverse Events by Treatment Group — 6; 3; 5; 6 Participants
Cervical Cancer
Primary: Number of Participants With Dose-Limiting Toxicities (DLTs) — 0; 2; 0 Participants
Cigarette Smoking-Related Carcinoma
Primary: Overall Satisfaction With Assigned Treatment on the Treatment Satisfaction Survey — 4.1; 3.7 units on a scale — p=0.0088
Healthy
Primary: Maximum Measured Concentration of BI 409306 in Plasma (Cmax) — 183; 175; 150 Nanomole per litre
Healthy
Primary: Mass Balance Recovery of Total Radioactivity in Urine and Faeces: Amount Excreted Within the Time Interval From 0 to the Time of the Last Quantifiable Data Point as a…
Healthy Study Participants
Primary: Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) — 83.3; 50.0; 100; 50.0 percentage of participants
Healthy
Primary: Percentage of Subjects With Drug-related Adverse Events (AEs) — 25; 0; 16.7; 0 Percentage of participants
Healthy
Primary: Area Under the Concentration-time Curve of BI 409306 in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz) — NA; NA nanomole*hour/liter…
Solid Tumors
Primary: Number of Participants With First Cycle Dose Limiting Toxicities (DLTs) — 0; 0; 0; 2 Participants
Healthy
Primary: Number of Subjects With Drug-related Adverse Events (AEs) — 0; 0; 0; 0 Participants